Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of bcr-abl1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib

  • Marcé, Silvia|||0000-0001-9128-6822
  • Xicoy, Blanca|||0000-0002-0295-1307
  • García, Olga
  • Cabezón, Marta|||0000-0001-5122-7481
  • Estrada Barreras, Natalia
  • Vélez, Patrícia
  • Boque, Concepcion
  • Sagüés, Miguel
  • Angona, Anna|||0000-0002-0965-9501
  • Teruel-Montoya, Raúl
  • Ferrer-Marín, Francisca|||0000-0002-9520-3243
  • Amat, Paula
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Ibarra, Mariana M.
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Cortés, Montserrat
  • Fernández-Ruiz, Andrés
  • Fontanals, Sandra|||0000-0002-4450-2227
  • Zamora, Lurdes|||0000-0003-1713-7110
The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Influence of Telomere length on the achievement of deep molecular response with Imatinib in chronic myeloid Leukemia patients

  • Estrada Barreras, Natalia
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Beier, Fabian|||0000-0002-3718-8217
  • García, Olga
  • Morales, Cristian
  • Boque, Concepcion
  • Sagüés, Miguel
  • Ferreira, Monica S. Ventura|||0000-0002-1437-1342
  • Vallansot, Rolando|||0000-0002-3915-7502
  • Marcé, Silvia|||0000-0001-9128-6822
  • Cabezón, Marta|||0000-0001-5122-7481
  • Brümmendorf, Tim H.|||0000-0002-9677-3723
  • Zamora, Lurdes|||0000-0003-1713-7110
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosis have been associated with this level of response. Telomere length (TL) in peripheral blood cells of patients with CML has been related to disease stage, response to therapy and disease progression, but little is known about its role on DMR. In this study, we analyzed if age-adjusted TL (referred as "delta-TL") at diagnosis of chronic phase (CP)-CML might correlate with the achievement of DMR under first-line imatinib treatment. TL from 96 CP-CML patients had been retrospectively analyzed at diagnosis by monochrome multiplex quantitative PCR. We observed that patients with longer age-adjusted telomeres at diagnosis had higher probabilities to achieve DMR with imatinib than those with shortened telomeres (P = 0.035 when delta-TL was studied as a continuous variable and P = 0.047 when categorized by the median). Moreover, patients carrying long telomeres also achieved major molecular response significantly earlier (P = 0.012). This study provides proof of concept that TL has a role in CML biology and when measured at diagnosis of CP-CML could help to identify patients likely to achieve DMR to first-line imatinib treatment.